Integrated 18F-fluorodeoxyglucose-positron emission tomography/dynamic contrast-enhanced computed tomography to phenotype non-small cell lung carcinoma

Molecular Imaging

Volumn 11, Issue 5, 2012, Pages 353-360

  Shastry, Manu ^a,b,c   Miles, Kenneth A ^a,b,c   Win, Thida ^a,b,c   Janes, Sam M ^a,b,c   Endozo, Raymond ^a,b,c   Meagher, Marie ^a,b,c   Ell, Peter J ^a,b,c   Groves, Ashley M ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Worthing Hospital   (United Kingdom)

^c LISTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTED TOMOGRAPHY; CONTRAST-ENHANCED; DYNAMIC CONTRAST-ENHANCED; FLUORODEOXYGLUCOSE-POSITRON EMISSION TOMOGRAPHIES; FUNCTIONAL IMAGING; LUNG CANCER; MEAN AGES; MEDIAN VALUE; NON-SMALL CELL LUNG CARCINOMATA; PRE-TREATMENT; SPEARMAN RANK CORRELATION; SQUAMOUS CELL CARCINOMA; STANDARDIZED UPTAKE VALUES; TECHNICAL FAILURES; TUMOR METABOLISMS; TUMOR SIZE; TUMOR SUBTYPES;

BIOLOGICAL ORGANS; DISEASES; METABOLISM; MOLECULAR IMAGING; PATIENT TREATMENT; POSITRON EMISSION TOMOGRAPHY; TUMORS;

COMPUTERIZED TOMOGRAPHY;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; CANCER STAGING; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; NONPARAMETRIC TEST; PATHOLOGY; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDY; SCINTISCANNING;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR IMAGING; NEOPLASM STAGING; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; STATISTICS, NONPARAMETRIC;

EID: 84872649797     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2011.00052     Document Type: Article

References (36)

1. American Cancer Society. Cancer facts and figures. Atlanta (GA): American Cancer Society; 2007.
2. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361:32-9, doi:10.1056/ NEJMoa0900043.
3. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-37, doi:10.1056/NEJMoa022136.
4. Ng QS, Goh V, Fichte H, et al. Lung cancer perfusion at multidetector row CT: reproducibility of whole tumor quantitative measurements. Radiology 2006;239:547-53, doi:10.1148/radiol. 2392050568.
5. de Langen AJ, van den Boogaart V, Lubberink M, et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrastenhanced MRI. J Nucl Med 2011;52:48-55, doi:10.2967/jnumed. 110.078261.
6. Lim E, Baldwin D, Beckles M, et al. Guidelines on the radical management of patients with lung cancer. Thorax 2010;65 Suppl 3:iii1-27, doi:10.1136/thx.2010.145938.
7. Miles KA, Griffiths MR, Keith CJ. Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:22-8, doi:10.1007/s00259-005- 1932-7.
8. Komar G, Kauhanen S, Liukko K, et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009;15:5511-7, doi:10.1158/1078- 0432.CCR-09-0414.
9. Groves AM, Wishart GC, Shastry M, et al. Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT. Eur J Nucl Med Mol Imaging 2009;36:416-21, doi:10.1007/s00259-008-0948-1.
10. Bisdas S, Spicer K, Rumboldt Z. Whole-tumor perfusion CT parameters and glucose metabolism measurements in head and neck squamous cell carcinomas: a pilot study using combined positron-emission tomography/CT imaging. AJNR Am J Neuroradiol 2008;29:1376-81, doi:10.3174/ajnr.A1111.
11. Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008;26:4449-57, doi:10.1200/JCO.2007.15.4385.
12. Mankoff D, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500-9.
13. Groves AM, Shastry M, Rodriguez-Justo M, et al. 18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging 2011;38:46-52, doi:10.1007/s00259-010- 1590-2.
14. Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002;62: 51-60, doi:10.1016/S0167-8140(01)00470-4.
15. Miles KA. Measurement of tissue perfusion by dynamic computed tomography. Br J Radiol 1991;64:409-12, doi:10.1259/0007-1285- 64-761-409.
16. Miles KA, Griffiths MR, Fuentes MA. Standardised perfusion value: a universal contrast enhancement scale that correlates with FDG-PET in lung cancer. Radiology 2001;220:548-53.
17. Miles KA, Young H, Chica SL, et al. Quantitative contrast-enhanced computed tomography: is there a need for system calibration? Eur Radiol 2007;17:919-26, doi:10.1007/s00330-006-0424-x.
18. Freeman GH, Halton JH. Note on exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 1951;38:141-9.
19. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6: 244-85, doi:10.1097/JTO.0b013e318206a221.
20. Brunelli A, Charloux A, Bolliger CT, et al. European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009;34:17-41, doi:10.1183/ 09031936.00184308.
21. Al-Sarraf N, Gately K, Lucey J, et al. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothorac Surg 2008;34:892-7, doi:10.1016/j.ejcts.2008.07.023.
22. Na II, Byun BH, Kim KM, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a singleinstitution retrospective analysis. Lung Cancer 2010;67:76-80, doi:10.1016/j.lungcan.2009.03.010.
23. Van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer 2006;118:883-8.
24. Yi CA, Lee KS, Kim BT, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 2006;47:443-50.
25. Christensen JA, Nathan MA, Mullan BP, et al. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus noduleenhancement CT. AJR Am J Roentgenol 2006;187:1361-7, doi:10.2214/AJR.05.1166.
26. Tateishi U, Nishihara H, Tsukamoto E, et al. Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 2002;26: 185-90, doi:10.1097/00004728- 200203000-00004.
27. Magat J, Jordan BF, Cron GO, et al. Noninvasive mapping of spontaneous fluctuations in tumor oxygenation using 19F MRI. Med Phys 2010;37:5434-41, doi:10.1118/1.3484056.
28. Toffoli S, Michiels C. Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J 2008; 275:2991-3002, doi:10.1111/j.1742-4658.2008.06454.x.
29. Lanzen J, Braun RD, Klitzman B, et al. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res 2006;66: 2219-23, doi:10.1158/0008-5472.CAN- 03-2958.
30. Higashi K, Ueda Y, Sakuma T, et al. Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules. J Nucl Med 2001;42:1489-96.
31. Groves AM, Win T, Ben Haim S, et al. Non FDG PET tracers in clinical oncology. Lancet Oncol 2007;8:822-30, doi:10.1016/S1470- 2045(07)70274-7.
32. Kayani I, Conry BG, Groves AM, et al. A comparison of 68Ga- DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50:1927-31, doi:10.2967/jnumed. 109.066639.
33. Specht JM, Kurland BF, Montgomery SK, et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res 2010;16:2803-10, doi:10.1158/1078-0432.CCR-10-0026.
34. Tseng J, Dunnwald LK, Schubert EK, et al. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 2004;45:1829-37.
35. Miles KA, Williams RE. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging 2008;8:81-6, doi:10.1102/ 1470-7330.2008.0011.
36. Win T, Groves AM, Ritchie AJ, et al. The effect of lung resection on pulmonary function and exercise capacity in lung cancer patients. Respir Care 2007;52:720-6.